Wednesday 16 July 2025

Pharma & Biotech Start-up & Scale-up News

Featured

Cantargia
A Swedish biotechnology company that specializes in the development of pharmaceuticals for various types of cancer and autoimmune/inflammatory diseases.
Biotechnology
Biocytogen inks antibody deal with BeOne, expanding strategic ties
10 July 2025
article
IDEAYA exercises option for license on Biocytogen’s IDE034
11 November 2024

Latest Ones To Watch News

Biotechnology
BRIEF—Genascence receives FDA RMAT designation for GNSC-001
16 July 2025
Biotechnology
Repare inks licensing deal with Debiopharm for lunresertib
16 July 2025
Biotechnology
FDA lifts partial hold on Kezar’s zetomipzomib trial
16 July 2025
More ones to watch news >
Reset all filters
Refine Search
Nanobiotix
Nanobiotix
Summit
Summit
MaaT Pharma
Nuvalent
UroGen Pharma
Tubulis
Neurocrine Biosciences
Axsome Therapeutics
Cidara Therapeutics
Halda Therapeutics
Opthea
OncoZenge
Soleno Therapeutics
GAIA
Alligator Bioscience
Pliant Therapeutics
Nuvation Bio
Enanta Pharmaceuticals
Basilea
Exsilio Therapeutics


Today's issue

J&J jumps on improved outlook
Pharmaceutical
J&J jumps on improved outlook
16 July 2025
Biotechnology
FDA probes ocular toxicity of Blenrep as GSK seeks new indications
16 July 2025
Biotechnology
Repare inks licensing deal with Debiopharm for lunresertib
16 July 2025
Biotechnology
FDA lifts partial hold on Kezar’s zetomipzomib trial
16 July 2025
Biotechnology
Lilly’s $1 billion CRISPR bet: what Verve means for gene editing
16 July 2025
Generics
Number of patent disputes continue to grow in Russian pharma market
16 July 2025
Pharmaceutical
Amvuttra gains UK approval for heart form of ATTR amyloidosis
16 July 2025

Company Spotlight

A Swedish biotechnology company that specializes in the development of pharmaceuticals for various types of cancer and autoimmune/inflammatory diseases.




Copyright © The Pharma Letter 2025   |   Headless Content Management with Blaze